ARA-290
Free Priority Shipping on Orders $99+
This peptide CANNOT be mixed with standard reconstitution solution. It MUST be reconstituted strictly with Acetic Acid. BulkGLP is not responsible for product loss or gelation resulting from the use of improper solvents.
ARA-290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the helix B surface domain of erythropoietin (EPO). Unlike EPO, this non-hematopoietic derivative is engineered to not stimulate red blood cell production. Instead, research investigates its selective affinity for the innate repair receptor (IRR), exploring its potential to modulate inflammatory cascades and promote tissue repair in laboratory models of neuropathy and cellular stress.
For Research Use Only. Not for human consumption.
$80.00
In stock
In stock
This peptide cannot be mixed with reconstitution solution it has to be mixed with acetic acid.
ARA-290 possesses the molecular formula C₅₁H₈₄N₁₆O₂₁ and consists of a specific sequence of 11 amino acids. It is chemically engineered to isolate the tissue-protective properties of erythropoietin (EPO) without engaging the homodimeric EPO receptor responsible for erythropoiesis. In experimental settings, this structural modification ensures that researchers can study its cellular repair mechanisms without inducing unwanted increases in red blood cell mass within in vivo models.
Scientific studies focus extensively on the interaction between ARA-290 and the innate repair receptor (IRR), which is a heterocomplex composed of the EPO receptor (EPOR) and the beta-common receptor (CD131). The IRR is typically upregulated by cells in response to metabolic stress, hypoxia, or physical injury. Upon binding to this specific receptor complex in vitro, the peptide is observed to initiate intracellular signaling cascades that inhibit apoptosis and downregulate the release of pro-inflammatory cytokines such as TNF-alpha and IL-6.
In animal models, ARA-290 is primarily utilized to investigate mechanisms of neuroprotection and peripheral nerve regeneration. Researchers administer the peptide in models of diabetic neuropathy and traumatic nerve injury to evaluate its impact on small nerve fiber density and the mitigation of tactile allodynia (neuropathic pain). Additionally, its capacity to enhance wound healing and reduce ischemic damage is actively explored in tissue culture and physiological laboratory models, making it a critical tool for mapping the pathways of innate cellular defense.
This product is strictly for laboratory and research purposes only. ARA-290 is not intended for human use, diagnostic, or therapeutic procedures. It serves as a reagent for scientific study and method development.
References
- Swartjes, M., et al. (2011). “ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief in a rat model of neuropathic pain.” Molecular Pain, 7(1), 71.
- Dahan, A., et al. (2013). “Targeting the innate repair receptor to treat neuropathy.” Current Opinion in Supportive and Palliative Care, 7(2), 136-142.
- Brines, M., et al. (2014). “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Molecular Medicine, 20(1), 358-366.